Nanocarrier fabrication and macromolecule drug delivery: challenges and opportunities

Therapeutic Delivery

Volumn 7, Issue 4, 2016, Pages 257-278

  Agrahari, Vibhuti ^a   Agrahari, Vivek ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

biologics; drug delivery; invasive route; macromolecule stability; nanotechnology; noninvasive route; peptide; protein

Indexed keywords

AFLIBERCEPT; BELATACEPT; BELIMUMAB; BLINATUMOMAB; BRENTUXIMAB VEDOTIN; DINUTUXIMAB; IPILIMUMAB; NANOCARRIER; NIVOLUMAB; OBINUTUZUMAB; OCRIPLASMIN; PEGINTERFERON; PEMBROLIZUMAB; RAMUCIRUMAB; RAXIBACUMAB; SECUKINUMAB; SILTUXIMAB; TRASTUZUMAB EMTANSINE; VEDOLIZUMAB; DENDRIMER; DRUG CARRIER; HYDROGEL; LIPOSOME; MACROMOLECULE; NANOPARTICLE; PEPTIDE; PROTEIN;

DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; ELECTROSPINNING; HUMAN; HYDROGEL; MACROMOLECULE; MICELLE; MOLECULAR WEIGHT; NANOFABRICATION; NANOTECHNOLOGY; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; SURFACE CHARGE; SURFACE PROPERTY; ADMINISTRATION AND DOSAGE; CHEMISTRY; METABOLISM;

DENDRIMERS; DRUG CARRIERS; HYDROGELS; LIPOSOMES; MACROMOLECULAR SUBSTANCES; NANOPARTICLES; PEPTIDES; PROTEINS;

EID: 84962073609     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde-2015-0012     Document Type: Review

References (105)

1. Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug. Discov. 13(9), 655-672 (2014).
2. Skalko-Basnet N. Biologics: the role of delivery systems in improved therapy. Biologics 8, 107-114 (2014).
3. Ibraheem D, Elaissari A, Fessi H. Administration strategies for proteins and peptides. Int. J. Pharm. 477(1-2), 578-589 (2014).
4. Renukuntla J, Vadlapudi AD, Patel A, Boddu SH, Mitra AK. Approaches for enhancing oral bioavailability of peptides and proteins. Int. J. Pharm. 447(1-2), 75-93 (2013).
5. Patel A, Cholkar K, Mitra AK. Recent developments in protein and peptide parenteral delivery approaches. Ther. Deliv. 5(3), 337-365 (2014).
6. Chung SW, Hil-Lal TA, Byun Y. Strategies for non-invasive delivery of biologics. J. Drug. Target. 20(6), 481-501 (2012).
7. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307(1), 93-102 (2006).
8. Prausnitz MR, Langer R. Transdermal drug delivery. Nat. Biotechnol. 26(11), 1261-1268 (2008).
9. Jitendra, Sharma PK, Bansal S, Banik A. Noninvasive routes of proteins and peptides drug delivery. Indian J. Pharm. Sci. 73(4), 367-375 (2011).
10. Depreter F, Pilcer G, Amighi K. Inhaled proteins: challenges and perspectives. Int. J. Pharm. 447(1-2), 251-280 (2013).
11. Smart AL, Gaisford S, Basit AW. Oral peptide and protein delivery: intestinal obstacles and commercial prospects. Exp. Opin. Drug. Deliv. 11(8), 1323-1335 (2014).
12. Fortuna A, Alves G, Serralheiro A, Sousa J, Falcao A. Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules. Eur. J. Pharm. Biopharm. 88(1), 8-27 (2014).
13. El-Hammadi MM, Arias JL. Nano-sized platforms for vaginal drug delivery. Curr. Pharm. Des. 21(12), 1633-1644 (2015).
14. Caon T, Jin L, Simoes CM, Norton RS, Nicolazzo JA. Enhancing the buccal mucosal delivery of peptide and protein therapeutics. Pharm. Res. 32(1), 1-21 (2015).
15. Senel S, Rathbone MJ, Cansiz M, Pather I. Recent developments in buccal and sublingual delivery systems. Exp. Opin. Drug. Deliv. 9(6), 615-628 (2012).
16. Dey B, Lagenaur LA, Lusso P. Protein-based HIV-1 microbicides. Curr. HIV Res. 11(7), 576-594 (2013).
17. Kim YC, Chiang B, Wu X, Prausnitz MR. Ocular delivery of macromolecules. J. Control. Rel. 190, 172-181 (2014).
18. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World J. Pharmacol. 2(2), 47-64 (2013).
19. Sebe I, Szabo P, Kallai-Szabo B, Zelko R. Incorporating small molecules or biologics into nanofibers for optimized drug release: a review. Int. J. Pharm. 494(1), 516-530 (2015).
20. Schwendener RA. Liposomes as vaccine delivery systems: a review of the recent advances. Ther. Adv. Vaccines 2(6), 159-182 (2014).
21. Martins S, Sarmento B, Ferreira DC, Souto EB. Lipid-based colloidal carriers for peptide and protein delivery-liposomes versus lipid nanoparticles. Int. J. Nanomed. 2(4), 595-607 (2007).
22. Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog. Polym. Sci. 39(2), 268-307 (2014).
23. Peppas NA, Wood KM, Blanchette JO. Hydrogels for oral delivery of therapeutic proteins. Exp. Opin. Biol. Ther. 4(6), 881-887 (2004).
24. Bruno BJ, Miller GD, Lim CS. Basics and recent advances in peptide and protein drug delivery. Ther. Deliv. 4(11), 1443-1467 (2013).
25. Vermonden T, Censi R, Hennink WE. Hydrogels for protein delivery. Chem. Rev. 112(5), 2853-2888 (2012).
26. Hoare TR, Kohane DS. Hydrogels in drug delivery: progress and challenges. Polymer 49(8), 1993-2007 (2008).
27. Oerlemans C, Bult W, Bos M, Storm G, Nijsen JFW, Hennink WE. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm. Res. 27(12), 2569-2589 (2010).
28. Lu Y, Park K. Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int. J. Pharm. 453(1), 198-214 (2013).
29. Li Z, Chen J, Sun W, Xu Y. Investigation of archaeosomes as carriers for oral delivery of peptides. Biochem. Biophys. Res. Commun. 394(2), 412-417 (2010).
30. Kaur G, Garg T, Rath G, Goyal AK. Archaeosomes: an excellent carrier for drug and cell delivery. Drug Deliv. 1-16 (2015).
31. Patel SP, Vaishya R, Pal D, Mitra AK. Novel pentablock copolymer-based nanoparticulate systems for sustained protein delivery. AAPS PharmSciTech 16(2), 327-343 (2015).
32. Patel SP, Vaishya R, Yang X, Pal D, Mitra AK. Novel thermosensitive pentablock copolymers for sustained delivery of proteins in the treatment of posterior segment diseases. Protein Pept. Lett. 21(11), 1185-1200 (2014).
33. Patel SP, Vaishya R, Patel A, Agrahari V, Pal D, Mitra AK. Optimization of novel pentablock copolymer based composite formulation for sustained delivery of peptide/ protein in the treatment of ocular diseases. J. Microencapsul. 11, 1-11 (2016).
34. Magnani M, Pierige F, Rossi L. Erythrocytes as a novel delivery vehicle for biologics: from enzymes to nucleic acidbased therapeutics. Ther. Deliv. 3(3), 405-414 (2012).
35. Muzykantov VR. Drug delivery by red blood cells: vascular carriers designed by mother nature. Exp. Opin. Drug. Deliv. 7(4), 403-427 (2010).
36. Rossi L, Serafini S, Pierige F et al. Erythrocyte-based drug delivery. Exp. Opin. Drug. Deliv. 2(2), 311-322 (2005).
37. Magnani M, Rossi L, Fraternale A et al. Erythrocytemediated delivery of drugs, peptides and modified oligonucleotides. Gene. Ther. 9(11), 749-751 (2002).
38. Witting M, Obst K, Friess W, Hedtrich S. Recent advances in topical delivery of proteins and peptides mediated by soft matter nanocarriers. Biotechnol. Adv. 33(6) 1355-69 (2015).
39. Andrade F, Videira M, Ferreira D, Sarmento B. Nanocarriers for pulmonary administration of peptides and therapeutic proteins. Nanomedicine (Lond). 6(1), 123-141 (2011).
40. Jain A, Jain A, Gulbake A, Shilpi S, Hurkat P, Jain SK. Peptide and protein delivery using new drug delivery systems. Crit. Rev. Ther. Drug Carrier. Syst. 30(4), 293-329 (2013).
41. Swaminathan J, Ehrhardt C. Liposomal delivery of proteins and peptides. Exp. Opin. Drug. Deliv. 9(12), 1489-1503 (2012).
42. Kammona O, Kiparissides C. Recent advances in nanocarrier-based mucosal delivery of biomolecules. J. Control. Rel. 161(3), 781-794 (2012).
43. Lu Y, Sun W, Gu Z. Stimuli-responsive nanomaterials for therapeutic protein delivery. J. Control. Release 194, 1-19 (2014).
44. Zhang T, Zhang C, Agrahari V, Murowchick JB, Oyler NA, Youan BB. Spray drying tenofovir loaded mucoadhesive andpH-sensitive microspheres intended for HIV prevention. Antiviral. Res. 97(3), 334-346 (2013).
45. Agrahari V, Zhang C, Zhang T et al. Hyaluronidase-sensitive nanoparticle templates for triggered release of HIV/AIDS microbicide in vitro. AAPS J. 16(2), 181-193 (2014).
46. Marianecci C, Di Marzio L, Rinaldi F et al. Niosomes from 80s to present: the state of the art. Adv. Colloid. Interface. Sci. 205, 187-206 (2014).
47. Mahale NB, Thakkar PD, Mali RG, Walunj DR, Chaudhari SR. Niosomes: novel sustained release nonionic stable vesicular systems-an overview. Adv. Colloid. Interface. Sci. 183-184, 46-54 (2012).
48. Umashankar MS, Sachdeva RK, Gulati M. Aquasomes: a promising carrier for peptides and protein delivery. Nanomedicine 6(3), 419-426 (2010).
49. Doshi N, Zahr AS, Bhaskar S, Lahann J, Mitragotri S. Red blood cell-mimicking synthetic biomaterial particles. Proc. Natl Acad. Sci. USA 106(51), 21495-21499 (2009).
50. Hu CM, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl Acad. Sci. USA 108(27), 10980-10985 (2011).
51. Piao JG, Wang L, Gao F, You YZ, Xiong Y, Yang L. Erythrocyte membrane is an alternative coating to polyethylene glycol for prolonging the circulation lifetime of gold nanocages for photothermal therapy. ACS Nano 8(10), 10414-10425 (2014).
52. Al-Qadi S, Grenha A, Carrion-Recio D, Seijo B, Remunan-Lopez C. Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulinloaded formulations. J. Control. Rel. 157(3), 383-390 (2012).
53. Derman S, Mustafaeva ZA, Abamor ES, Bagirova M, Allahverdiyev A. Preparation, characterization and immunological evaluation: canine parvovirus synthetic peptide loaded PLGA nanoparticles. J. Biomed. Sci. 22, 89 (2015).
54. Santander-Ortega MJ, Bastos-Gonzalez D, Ortega-Vinuesa JL, Alonso MJ. Insulin-loaded PLGA nanoparticles for oral administration: an in vitro physico-chemical characterization. J. Biomed. Nanotechnol. 5(1), 45-53 (2009).
55. Piras AM, Sandreschi S, Maisetta G, Esin S, Batoni G, Chiellini F. Chitosan nanoparticles for the linear release of model cationic Peptide. Pharm. Res. 32(7), 2259-2265 (2015).
56. Ham AS, Cost MR, Sassi AB, Dezzutti CS, Rohan LC. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm. Res. 26(3), 502-511 (2009).
57. Koetting MC, Guido JF, Gupta M, Zhang A, Peppas NA. pHresponsive and enzymatically-responsive hydrogel microparticles for the oral delivery of therapeutic proteins: effects of protein size, crosslinking density, and hydrogel degradation on protein delivery. J. Control. Rel. 221, 18-25 (2016).
58. Vaishya RD, Mandal A, Patel S, Mitra AK. Extended release microparticle-in-gel formulation of octreotide: effect of polymer type on acylation of peptide during in vitro release. Int. J. Pharm. 496(2), 676-688 (2015).
59. Mantripragada VP, Jayasuriya AC. IGF-1 release kinetics from chitosan microparticles fabricated using environmentally benign conditions. Mater. Sci. Eng. C Mater. Biol. Appl. 42, 506-516 (2014).
60. Tewes F, Gobbo OL, Ehrhardt C, Healy AM. Amorphous calcium carbonate based-microparticles for peptide pulmonary delivery. ACS Appl. Mater. Interfaces. 8(2), 1164-1175 (2016).
61. Rubinstein I, Ikezaki H, Onyuksel H. Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters. Int. J. Pharm. 316(1-2), 144-147 (2006).
62. Liau JJ, Hook S, Prestidge CA, Barnes TJ. A lipid based multicompartmental system: liposomes-in-double emulsion for oral vaccine delivery. Eur. J. Pharm. Biopharm. 97(Pt A), 15-21 (2015).
63. Fan T, Chen C, Guo H et al. Design and evaluation of solid lipid nanoparticles modified with peptide ligand for oral delivery of protein drugs. Eur. J. Pharm. Biopharm. 88(2), 518-528 (2014).
64. Sacchetti F, Marraccini C, D'arca D et al. Enhanced antihyperproliferative activity of human thymidylate synthase inhibitor peptide by solid lipid nanoparticle delivery. Colloids. Surf. B Biointerfaces. 136, 346-354 (2015).
65. Gainza G, Pastor M, Aguirre JJ et al. A novel strategy for the treatment of chronic wounds based on the topical administration of rhEGF-loaded lipid nanoparticles: in vitro bioactivity and in vivo effectiveness in healing-impaired db/db mice. J. Control. Rel. 185, 51-61 (2014).
66. Yang R, Gao RC, Cai CF et al. Preparation of gel-core-solid lipid nanoparticle: a novel way to improve the encapsulation of protein and peptide. Chem. Pharm. Bull. (Tokyo) 58(9), 1195-1202 (2010).
67. Gatti JW, Smithgall MC, Paranjape SM, Rolfes RJ, Paranjape M. Using electrospun poly(ethylene-oxide) nanofibers for improved retention and efficacy of bacteriolytic antibiotics. Biomed. Microdevices. 15(5), 887-893 (2013).
68. Wang J, An Q, Li D et al. Heparin and vascular endothelial growth factor loaded poly(L-lactide-co-caprolactone) nanofiber covered stent-graft for aneurysm treatment. J. Biomed. Nanotechnol. 11(11), 1947-1960 (2015).
69. Zhang YZ, Wang X, Feng Y, Li J, Lim CT, Ramakrishna S. Coaxial electrospinning of (fluorescein isothiocyanateconjugated bovine serum albumin)-encapsulated poly(epsilon-caprolactone) nanofibers for sustained release. Biomacromolecules 7(4), 1049-1057 (2006).
70. Cherian AK, Rana AC, Jain SK. Self-assembled carbohydrate-stabilized ceramic nanoparticles for the parenteral delivery of insulin. Drug. Dev. Ind. Pharm. 26(4), 459-463 (2000).
71. Pandey RS, Sahu S, Sudheesh MS, Madan J, Kumar M, Dixit VK. Carbohydrate modified ultrafine ceramic nanoparticles for allergen immunotherapy. Int. Immunopharmacol. 11(8), 925-931 (2011).
72. Krishnan L, Sad S, Patel GB, Sprott GD. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help. J. Immunol. 165(9), 5177-5185 (2000).
73. Moghassemi S, Hadjizadeh A, Omidfar K. Formulation and characterization of bovine serum albumin-loaded niosome. AAPS PharmSciTech doi:10. 1208/s12249-016-0487-1 (2016) (Epub ahead of print).
74. Pardakhty A, Varshosaz J, Rouholamini A. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int. J. Pharm. 328(2), 130-141 (2007).
75. Cholkar K, Gilger BC, Mitra AK. Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery. Transl. Vis. Sci. Technol. 4(3), 1 (2015).
76. Ashjari M, Khoee S, Mahdavian AR, Rahmatolahzadeh R. Self-assembled nanomicelles using PLGA-PEG amphiphilic block copolymer for insulin delivery: a physicochemical investigation and determination of CMC values. J. Mater. Sci. Mater. Med. 23(4), 943-953 (2012).
77. Gao GH, Park MJ, Li Y et al. The use of pH-sensitive positively charged polymeric micelles for protein delivery. Biomaterials 33(35), 9157-9164 (2012).
78. Ishii S, Kaneko J, Nagasaki Y. Development of a long-acting, protein-loaded, redox-active, injectable gel formed by a polyion complex for local protein therapeutics. Biomaterials 84, 210-218 (2016).
79. Tong X, Lee S, Bararpour L, Yang F. Long-Term controlled protein release from poly(ethylene glycol) hydrogels by modulating mesh size and degradation. Macromol. Biosci. 15(12), 1679-1686 (2015).
80. Agrahari V, Agrahari V, Hung WT, Christenson L, Mitra AK. Composite nanoformulation therapeutics for long term ocular delivery of macromolecules. Mol. Pharm. doi:10. 1021/acs. molpharmaceut. 5b00828 (2016) (Epub ahead of print).
81. He H, Ye J, Wang Y et al. Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application. J. Control. Rel. 176, 123-132 (2014).
82. Cremel M, Guerin N, Horand F, Banz A, Godfrin Y. Red blood cells as innovative antigen carrier to induce specific immune tolerance. Int. J. Pharm. 443(1-2), 39-49 (2013).
83. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2(12), 751-760 (2007).
84. Sanhai WR, Sakamoto JH, Canady R, Ferrari M. Seven challenges for nanomedicine. Nat. Nanotechnol. 3(5), 242-244 (2008).
85. Hu CM, Aryal S, Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther. Deliv. 1(2), 323-334 (2010).
86. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine-challenge and perspectives. Angew. Chem. Int. Ed. Engl. 48(5), 872-897 (2009).
87. Yoo JW, Irvine DJ, Discher DE, Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat. Rev. Drug. Discov. 10(7), 521-535 (2011).
88. Salmaso S, Caliceti P. Stealth properties to improve therapeutic efficacy of drug nanocarriers. J. Drug. Deliv. 2013, 374252 (2013).
89. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug. Discov. 7(9), 771-782 (2008).
90. Van Vlerken LE, Vyas TK, Amiji MM. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res. 24(8), 1405-1414 (2007).
91. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly (ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. Engl. 49(36), 6288-6308 (2010).
92. Vllasaliu D, Fowler R, Stolnik S. PEGylated nanomedicines: recent progress and remaining concerns. Exp. Opin. Drug. Deliv. 11(1), 139-154 (2014).
93. Yoo JW, Chambers E, Mitragotri S. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr. Pharm. Des. 16(21), 2298-2307 (2010).
94. Morachis JM, Mahmoud EA, Almutairi A. Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles. Pharmacol. Rev. 64(3), 505-519 (2012).
95. Ernsting MJ, Murakami M, Roy A, Li SD. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J. Control. Rel. 172(3), 782-794 (2013).
96. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc. Natl Acad. Sci. USA 103(13), 4930-4934 (2006).
97. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5(4), 505-515 (2008).
98. Merkel TJ, Herlihy KP, Nunes J, Orgel RM, Rolland JP, Desimone JM. Scalable, shape-specific, top-down fabrication methods for the synthesis of engineered colloidal particles. Langmuir 26(16), 13086-13096 (2010).
99. Perry JL, Herlihy KP, Napier ME, Desimone JM. PRINT: a novel platform toward shape and size specific nanoparticle theranostics. Acc. Chem. Res. 44(10), 990-998 (2011).
100. Champion JA, Katare YK, Mitragotri S. Making polymeric micro-and nanoparticles of complex shapes. Proc. Natl Acad. Sci. USA 104(29), 11901-11904 (2007).
101. Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science 288(5473), 2051-2054 (2000).
102. Rodriguez PL, Harada T, Christian DA, Pantano DA, Tsai RK, Discher DE. Minimal 'self ' peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339(6122), 971-975 (2013).
103. Youm I, Agrahari V, Murowchick JB, Youan BB. Uptake and cytotoxicity of docetaxel-loaded hyaluronic acid-grafted oily core nanocapsules in MDA-MB 231 cancer cells. Pharm. Res. 31(9), 2439-2452 (2014).
104. Ducat E, Brion M, Lecomte F, Evrard B, Piel G. The experimental design as practical approach to develop and optimize a formulation of peptide-loaded liposomes. AAPS PharmSciTech 11(2), 966-975 (2010).
105. Gupta S, Kaisheva E. Development of a multidose formulation for a humanized monoclonal antibody using experimental design techniques. AAPS PharmSciTech 5(2), E8 (2003).